OBJECTIVE: To evaluate the impact of a nonstandard ventilation strategy on survival in congenital diaphragmatic hernia (CDH). BACKGROUND: Despite recent advances, including nitric oxide, CDH remains an unsolved problem with a mortality rate of 35% to 50%. Hyperventilation and alkalization remain common therapies. METHODS: In 1992, the authors prospectively abandoned hyperventilation and alkalization. Patients are lightly sedated and ventilated with the lowest pressure providing adequate chest movement, and the rate is set to patient comfort. Nitric oxide and extracorporeal membrane oxygenation (ECMO) are reserved for life-threatening instability. Surgical repair is delayed 1 to 5 days. Sixty consecutive patients are compared with 29 previous patients treated with hyperventilation and alkalization, 13 before and 16 after the availability of ECMO. RESULTS: Overall, 47 of 60 patients (78%) in study era 3 survived compared with 2 of 13 (15%) in the hyperventilation era and 7 of 16 (44%) in the hyperventilation/ECMO era (p < 0.0001). The disease severity and the incidence of associated anomalies did not differ between groups. To compare management strategies, patients who had treatment withheld because of lethal associated conditions were then removed from analysis. Peak inspiratory pressure and arterial pH were lower (p < 0.0001) and Paco2 was higher (p < 0.05) in era 3 than in the previous eras. The rate of pneumothorax (1.9%) decreased (p < 0.0001). In era 3, survival was 47 of 53 (89%) treated patients, and 23 of 25 inborn patients with isolated CDH survived (92%). CONCLUSIONS: Nonstandard ventilatory support of patients with CDH has led to significantly improved survival rates. This study sets a survival benchmark and strongly suggests the negative effects of hyperventilation and alkalization.
OBJECTIVE: To evaluate the impact of a nonstandard ventilation strategy on survival in congenital diaphragmatic hernia (CDH). BACKGROUND: Despite recent advances, including nitric oxide, CDH remains an unsolved problem with a mortality rate of 35% to 50%. Hyperventilation and alkalization remain common therapies. METHODS: In 1992, the authors prospectively abandoned hyperventilation and alkalization. Patients are lightly sedated and ventilated with the lowest pressure providing adequate chest movement, and the rate is set to patient comfort. Nitric oxide and extracorporeal membrane oxygenation (ECMO) are reserved for life-threatening instability. Surgical repair is delayed 1 to 5 days. Sixty consecutive patients are compared with 29 previous patients treated with hyperventilation and alkalization, 13 before and 16 after the availability of ECMO. RESULTS: Overall, 47 of 60 patients (78%) in study era 3 survived compared with 2 of 13 (15%) in the hyperventilation era and 7 of 16 (44%) in the hyperventilation/ECMO era (p < 0.0001). The disease severity and the incidence of associated anomalies did not differ between groups. To compare management strategies, patients who had treatment withheld because of lethal associated conditions were then removed from analysis. Peak inspiratory pressure and arterial pH were lower (p < 0.0001) and Paco2 was higher (p < 0.05) in era 3 than in the previous eras. The rate of pneumothorax (1.9%) decreased (p < 0.0001). In era 3, survival was 47 of 53 (89%) treated patients, and 23 of 25 inbornpatients with isolated CDH survived (92%). CONCLUSIONS: Nonstandard ventilatory support of patients with CDH has led to significantly improved survival rates. This study sets a survival benchmark and strongly suggests the negative effects of hyperventilation and alkalization.
Authors: D K Nakayama; M R Harrison; D H Chinn; P W Callen; R A Filly; M S Golbus; A A De Lorimier Journal: J Pediatr Surg Date: 1985-04 Impact factor: 2.545
Authors: M R Harrison; G B Mychaliska; C T Albanese; R W Jennings; J A Farrell; S Hawgood; P Sandberg; A H Levine; E Lobo; R A Filly Journal: J Pediatr Surg Date: 1998-07 Impact factor: 2.545
Authors: David W Kays; Saleem Islam; Joy M Perkins; Shawn D Larson; Janice A Taylor; James L Talbert Journal: J Pediatr Surg Date: 2015-03-14 Impact factor: 2.545
Authors: David W Kays; Saleem Islam; Douglas S Richards; Shawn D Larson; Joy M Perkins; James L Talbert Journal: J Am Coll Surg Date: 2014-02-07 Impact factor: 6.113
Authors: Christopher A Guidry; Tjasa Hranjec; Bradley M Rodgers; Bartholomew Kane; Eugene D McGahren Journal: J Am Coll Surg Date: 2012-02-28 Impact factor: 6.113
Authors: Nikesh R Lath; Csaba Galambos; Alejandro Best Rocha; Marcus Malek; George K Gittes; Douglas A Potoka Journal: Am J Physiol Lung Cell Mol Physiol Date: 2011-11-23 Impact factor: 5.464
Authors: Kevin P Lally; Pamela A Lally; Krisa P Van Meurs; Desmond J Bohn; Carl F Davis; Bradley Rodgers; Jatinder Bhatia; Golde Dudell Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: Jennifer R Benjamin; Kathryn E Gustafson; P Brian Smith; Kirsten M Ellingsen; K Brooke Tompkins; Ronald N Goldberg; C Michael Cotten; Ricki F Goldstein Journal: J Pediatr Surg Date: 2013-04 Impact factor: 2.545